NCT06390826 2026-03-17
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
NCT03673501 2026-02-05
INTRIGUE
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT01391962 2026-02-02
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03091192 2026-01-23
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting